Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

[
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
[og_img]
https://www.investing.com/news/press-releases/bicara-therapeutics-announces-first-patients-enrolled-in-fortifihn01-a-pivotal-phase-23-clinical-trial-of-ficerafusp-alfa-in-1l-recurrentmetastatic-head-and-neck-squamous-cell-carcinoma-93CH-3862808


Investing.com